Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.
Identifieur interne : 003231 ( PubMed/Checkpoint ); précédent : 003230; suivant : 003232Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.
Auteurs : J. Cinatl [Allemagne] ; B. Morgenstern ; G. Bauer ; P. Chandra ; H. Rabenau ; H W DoerrSource :
- Lancet (London, England) [ 1474-547X ] ; 2003.
Descripteurs français
- KwdFr :
- MESH :
- pharmacologie : Acide glycyrrhizique, Antiviraux.
- physiologie : Coronavirus.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- Animaux, Cellules Vero, Coronavirus, Glycyrrhiza, Humains, Réplication virale.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Antiviral Agents, Glycyrrhizic Acid.
- chemistry : Glycyrrhiza.
- drug effects : Coronavirus, Virus Replication.
- drug therapy : Severe Acute Respiratory Syndrome.
- physiology : Coronavirus.
- Animals, Chlorocebus aethiops, Humans, Vero Cells.
Abstract
The outbreak of SARS warrants the search for antiviral compounds to treat the disease. At present, no specific treatment has been identified for SARS-associated coronavirus infection. We assessed the antiviral potential of ribavirin, 6-azauridine, pyrazofurin, mycophenolic acid, and glycyrrhizin against two clinical isolates of coronavirus (FFM-1 and FFM-2) from patients with SARS admitted to the clinical centre of Frankfurt University, Germany. Of all the compounds, glycyrrhizin was the most active in inhibiting replication of the SARS-associated virus. Our findings suggest that glycyrrhizin should be assessed for treatment of SARS.
DOI: 10.1016/s0140-6736(03)13615-x
PubMed: 12814717
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:12814717Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.</title>
<author><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J" last="Cinatl">J. Cinatl</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Medical Virology, Frankfurt University Medical School, Paul-Ehrlich Str 40, D-60596, Frankfurt, Germany. cinatl@em.uni-frankfurt.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Medical Virology, Frankfurt University Medical School, Paul-Ehrlich Str 40, D-60596, Frankfurt</wicri:regionArea>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B" last="Morgenstern">B. Morgenstern</name>
</author>
<author><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G" last="Bauer">G. Bauer</name>
</author>
<author><name sortKey="Chandra, P" sort="Chandra, P" uniqKey="Chandra P" first="P" last="Chandra">P. Chandra</name>
</author>
<author><name sortKey="Rabenau, H" sort="Rabenau, H" uniqKey="Rabenau H" first="H" last="Rabenau">H. Rabenau</name>
</author>
<author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:12814717</idno>
<idno type="pmid">12814717</idno>
<idno type="doi">10.1016/s0140-6736(03)13615-x</idno>
<idno type="wicri:Area/PubMed/Corpus">003315</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003315</idno>
<idno type="wicri:Area/PubMed/Curation">003315</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003315</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003231</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003231</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.</title>
<author><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J" last="Cinatl">J. Cinatl</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Medical Virology, Frankfurt University Medical School, Paul-Ehrlich Str 40, D-60596, Frankfurt, Germany. cinatl@em.uni-frankfurt.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Medical Virology, Frankfurt University Medical School, Paul-Ehrlich Str 40, D-60596, Frankfurt</wicri:regionArea>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B" last="Morgenstern">B. Morgenstern</name>
</author>
<author><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G" last="Bauer">G. Bauer</name>
</author>
<author><name sortKey="Chandra, P" sort="Chandra, P" uniqKey="Chandra P" first="P" last="Chandra">P. Chandra</name>
</author>
<author><name sortKey="Rabenau, H" sort="Rabenau, H" uniqKey="Rabenau H" first="H" last="Rabenau">H. Rabenau</name>
</author>
<author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name>
</author>
</analytic>
<series><title level="j">Lancet (London, England)</title>
<idno type="eISSN">1474-547X</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Chlorocebus aethiops</term>
<term>Coronavirus (drug effects)</term>
<term>Coronavirus (physiology)</term>
<term>Glycyrrhiza (chemistry)</term>
<term>Glycyrrhizic Acid (pharmacology)</term>
<term>Humans</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Vero Cells</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acide glycyrrhizique (pharmacologie)</term>
<term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cellules Vero</term>
<term>Coronavirus ()</term>
<term>Coronavirus (physiologie)</term>
<term>Glycyrrhiza ()</term>
<term>Humains</term>
<term>Réplication virale ()</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Glycyrrhizic Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Glycyrrhiza</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Acide glycyrrhizique</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Humans</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Cellules Vero</term>
<term>Coronavirus</term>
<term>Glycyrrhiza</term>
<term>Humains</term>
<term>Réplication virale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The outbreak of SARS warrants the search for antiviral compounds to treat the disease. At present, no specific treatment has been identified for SARS-associated coronavirus infection. We assessed the antiviral potential of ribavirin, 6-azauridine, pyrazofurin, mycophenolic acid, and glycyrrhizin against two clinical isolates of coronavirus (FFM-1 and FFM-2) from patients with SARS admitted to the clinical centre of Frankfurt University, Germany. Of all the compounds, glycyrrhizin was the most active in inhibiting replication of the SARS-associated virus. Our findings suggest that glycyrrhizin should be assessed for treatment of SARS.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12814717</PMID>
<DateCompleted><Year>2003</Year>
<Month>07</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>361</Volume>
<Issue>9374</Issue>
<PubDate><Year>2003</Year>
<Month>Jun</Month>
<Day>14</Day>
</PubDate>
</JournalIssue>
<Title>Lancet (London, England)</Title>
<ISOAbbreviation>Lancet</ISOAbbreviation>
</Journal>
<ArticleTitle>Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.</ArticleTitle>
<Pagination><MedlinePgn>2045-6</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The outbreak of SARS warrants the search for antiviral compounds to treat the disease. At present, no specific treatment has been identified for SARS-associated coronavirus infection. We assessed the antiviral potential of ribavirin, 6-azauridine, pyrazofurin, mycophenolic acid, and glycyrrhizin against two clinical isolates of coronavirus (FFM-1 and FFM-2) from patients with SARS admitted to the clinical centre of Frankfurt University, Germany. Of all the compounds, glycyrrhizin was the most active in inhibiting replication of the SARS-associated virus. Our findings suggest that glycyrrhizin should be assessed for treatment of SARS.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cinatl</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Institute of Medical Virology, Frankfurt University Medical School, Paul-Ehrlich Str 40, D-60596, Frankfurt, Germany. cinatl@em.uni-frankfurt.de</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Morgenstern</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bauer</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chandra</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rabenau</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Doerr</LastName>
<ForeName>H W</ForeName>
<Initials>HW</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Lancet</MedlineTA>
<NlmUniqueID>2985213R</NlmUniqueID>
<ISSNLinking>0140-6736</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6FO62043WK</RegistryNumber>
<NameOfSubstance UI="D019695">Glycyrrhizic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006035" MajorTopicYN="N">Glycyrrhiza</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019695" MajorTopicYN="N">Glycyrrhizic Acid</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year>
<Month>6</Month>
<Day>20</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2003</Year>
<Month>7</Month>
<Day>11</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2003</Year>
<Month>6</Month>
<Day>20</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">12814717</ArticleId>
<ArticleId IdType="pii">S014067360313615X</ArticleId>
<ArticleId IdType="doi">10.1016/s0140-6736(03)13615-x</ArticleId>
<ArticleId IdType="pmc">PMC7112442</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1997 Jul;71(7):5227-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9188590</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2003 Mar;58(1):73-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12719009</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2002 Feb 27;513(2-3):208-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11904152</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>District de Darmstadt</li>
<li>Hesse (Land)</li>
</region>
<settlement><li>Francfort-sur-le-Main</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G" last="Bauer">G. Bauer</name>
<name sortKey="Chandra, P" sort="Chandra, P" uniqKey="Chandra P" first="P" last="Chandra">P. Chandra</name>
<name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name>
<name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B" last="Morgenstern">B. Morgenstern</name>
<name sortKey="Rabenau, H" sort="Rabenau, H" uniqKey="Rabenau H" first="H" last="Rabenau">H. Rabenau</name>
</noCountry>
<country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J" last="Cinatl">J. Cinatl</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003231 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003231 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:12814717 |texte= Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:12814717" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |